, is an antiamoebic and anthelmintic agent. It is indicated for amoebiasis, helminthiasis, giardiasis, fascioliasis, trichomoniasis and cryptosporidiosis, including those with AIDS or HIV infections 2,3 . It is not yet official in any of the pharmacopoeia. Literature survey revealed RP-HPLC method for its determination in bulk drug and pharmaceutical formulation 4 . Ofloxacin (OFX), 9-ß uoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-di)-1,4-benzoxazine-6-carboxylic acid 5 , is useful in the treatment of genitourinary, respiratory, gastrointestinal, skin and soft tissue infections, peritonitis and gonorhoea 6 . Few UV spectrophotometric methods and HPLC methods have been reported for the estimation of ofloxacin, especially in body fluids and blood plasma as well as from pharmaceutical preparations [7][8][9][10][11] . OFX is ofÞ cial in BP and USP NF 12,13 . Literature review revealed that no HPLC method is yet reported for the simultaneous estimation of the NTZ and OFX in combined tablet dosage form at single wavelength. Therefore, it was thought worthwhile to develop simple, precise, accurate reverse phase HPLC method for simultaneous estimation of NTZ and OFX in combined tablet dosage form. LC system (Shimadzu LC 10AT VP HPLC) used consist of pump with universal loop injector (Rheodyne 7725) of injection capacity 20 µl. Detector consists of photodiode array detector SPD-10 AVP, Shimadzu; the reversed phase column used was Luna C 18 (5 µm, 25 cm × 4.6 mm i.d.) Phenomenex, USA, at ambient temperature. Among the several mobile phases used for the simultaneous estimation of NTZ and OFX, acetonitrile:0.25 M potassium dihydrogen phosphate buffer (80:20) with 0.5%v/v of triethylamine, adjusted to pH 2.5 using orthophosphoric acid was found to be most suitable and was Þ ltered through 0.2 micron membrane Þ lter.
Nitazoxanide (NTZ), chemically N-(5-nitro-2-thiazoly) salicylamide acetate 1 , is an antiamoebic and anthelmintic agent. It is indicated for amoebiasis, helminthiasis, giardiasis, fascioliasis, trichomoniasis and cryptosporidiosis, including those with AIDS or HIV infections 2,3 . It is not yet official in any of the pharmacopoeia. Literature survey revealed RP-HPLC method for its determination in bulk drug and pharmaceutical formulation 4 . Ofloxacin (OFX), 9-ß uoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-di)-1,4-benzoxazine-6-carboxylic acid 5 , is useful in the treatment of genitourinary, respiratory, gastrointestinal, skin and soft tissue infections, peritonitis and gonorhoea 6 . Few UV spectrophotometric methods and HPLC methods have been reported for the estimation of ofloxacin, especially in body fluids and blood plasma as well as from pharmaceutical preparations [7] [8] [9] [10] [11] . OFX is ofÞ cial in BP and USP NF 12, 13 . Literature review revealed that no HPLC method is yet reported for the simultaneous estimation of the NTZ and OFX in combined tablet dosage form at single wavelength. Therefore, it was thought worthwhile to develop simple, precise, accurate reverse phase HPLC method for simultaneous estimation of NTZ and OFX in combined tablet dosage form. LC system (Shimadzu LC 10AT VP HPLC) used consist of pump with universal loop injector (Rheodyne 7725) of injection capacity 20 µl. Detector consists of photodiode array detector SPD-10 AVP, Shimadzu; the reversed phase column used was Luna C 18 (5 µm, 25 cm × 4.6 mm i.d.) Phenomenex, USA, at ambient temperature. Among the several mobile phases used for the simultaneous estimation of NTZ and OFX, acetonitrile:0.25 M potassium dihydrogen phosphate buffer (80:20) with 0.5%v/v of triethylamine, adjusted to pH 2.5 using orthophosphoric acid was found to be most suitable and was Þ ltered through 0.2 micron membrane Þ lter.
Stock solutions of NTZ and OFX 1mg/ml concentration were prepared in mobile phase. 50 mg of NTZ was dissolved in 10 ml of acetonitrile and diluted to 50 ml by the mobile phase, and concentration of 1 mg/ml was obtained. They were further diluted with mobile phase to obtained required concentration of 5, 10, 15, 20, 25 µg/ml. In the similar way 50 mg of OFX was dissolved in 10 ml of buffer and further diluted with 40 ml of mobile phase, and the concentration of 1 mg/ml was obtained. They were further diluted with mobile phase to obtained required concentration of 5, 10, 15, 20, 25 µg/ml. All solutions were stored at room temperature; these solutions were shown to be stable during the period of study.
A volume of 20 µl of each standard after Þ ltration by 0.2-micron membrane Þ lter was injected into column. All measurements were repeated Þ ve times for each concentration and respective calibration curves were constructed by plotting the peak area versus the corresponding drug concentration. The slope and correlation coefÞ cients were determined (Table 1) .
To determine the content of NTZ and OFX in tablet dosage form (Label claim: 500 mg of NTZ and 200 mg of OFX); twenty tablets were weighed; their average weight was determined and Þ nely powdered. Then triturate tablet dosage form equivalent to 50 mg of NTZ was taken and was dissolved in 10 ml of mobile phase by stirring for 2 min. and the volume was made up to 50 ml by mobile phase. Then 1 ml from that solution was taken and diluted with mobile phase to make up to 10 ml. The final solution was filtered by 0.2-micron membrane filter by using injection Þ lter. Then with the help of pipette 0.5, 1.0, 1.5, 2.0, 2.5 ml of the Þ ltered solution taken in small test tubes and diluted up to 10 ml of each respectively which contain 5:2, 10:4, 15:6, 20:8, and 25:10 µg/ml of NTZ and OFX respectively. A 20 µl of the above dilutions were injected one by one to the HPLC with the help of Hamilton Syringe. The results are reported in Table 2 and the amount of both the drugs was determined.
To check the accuracy of the developed methods and to study the interference of formulation additives, analytical recovery experiments were carried out by standard addition method. From the total amount of drug found, the percentage recovery was calculated. The results of the analysis are reported in Table 3 and 4.
Optimization of mobile phase and flow rate were performed based on peak parameters such as height, tailing factor, theoretical plates, capacity factor, run time and resolution. The mobile phase acetonitrile:0.25 M potassium dihydrogen phosphate buffer (80:20) with 0.5%v/v of triethylamine, adjusted to pH 2.5 using orthophosphoric acid was found to be satisfactory and gave two symmetrical and well resolved peaks for NTZ and OFX. The resolution between NTZ and OFX was found to be 7.17, which indicates good separation for both the compounds. The retention time for NTZ and OFX were 3.38 min and 2.19 min, respectively (Þ g. 1). The wavelength 320 nm was selected for simultaneous determination based on maximum absorption of both drugs and best detector response at this wavelength. The calibration curve for NTZ and OFX was obtained by plotting the peak area of NTZ and OFX versus their concentration over the range of 5-25 µg/ml and were found to be linear with r=0.9987 and 0.9995 for NTZ and OFX, respectively. The detection limit for NTZ and OFX were 0.14 µg/ml and 0.59 µg/ ml, respectively. The quantitation limit for NTZ and OFX were 0.43 µg/ml and 1.80 µg/ml, respectively, which suggested that a nanogram quantity of both the compounds can be estimated accurately. The validation and system suitability parameters are shown in Table  1 . The recoveries of NTZ and OFX were found to be in the range 99.06-100.58% and 99.05-101.60%, respectively (Table 3) . Repeatability, accuracy and precision data are reported in Table 4 .
The liquid chromatographic method was applied for the simultaneous determination of NTZ and OFX in combined tablet dosage form. The result of analysis of tablet formulation containing 5 to 25 mg of NTZ and 2 to 10 mg of OFX revel SD ranging from 0.012 to 0.142 and%RSD ranging from 0.07 to 0.57 in the case of NTZ and 0.002 to 0.116 and 0.23 to 1.15 in the case of OFX, all values being mean of five replicates (Table 2) .
Proposed method describes a new RPHPLC method for the determination of NTZ and OFX in combined tablet dosage form. The method gives good resolution between both the compounds and with a short analysis time (<5 min). The method was validated and found to be simple, sensitive, accurate and precise. Percentage of recovery shows that the method is free from interference of the excipient used in the formulation. Therefore, the proposed method can be used for routine analysis of NTZ and OFX in their combined tablet dosage form. 
